Literature DB >> 1662693

Characterization of a major antigenic region on gp55 of human cytomegalovirus.

M Silvestri1, V A Sundqvist, U Rudén, B Wahren.   

Abstract

A major antigenic region localized to the C-terminal part of the 55K glycoprotein of human cytomegalovirus (HCMV) was mapped using synthetic peptides. Analysis of the region with six sera from healthy anti-HCMV seropositive blood donors showed that the length of the reactive sequence varied between four and eight amino acids (aa). The shortest sequence recognized was VTSG (aa 798 to 801 of the 130K precursor protein), but most sera required the three or four residues C-terminal to this to react, giving a major site of VTSGSTKD (aa 798 to 805). Using peptides immobilized on polyethylene pins, the importance of both interior (between aa essential for the binding of an antibody) and extension spacer residues was evident. Free peptides containing the reactive sequence were prepared for use in a conventional ELISA and optimal pH conditions for coating were determined. The best results were achieved at pH 2 to 3, which is in agreement with the advantageous net charge of these peptides at this low pH. Anti-HCMV positive sera showed a sensitivity of approximately 50% for both peptides on polyethylene pins and peptides coated onto plates.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662693     DOI: 10.1099/0022-1317-72-12-3017

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus.

Authors:  B Wagner; B Kropff; H Kalbacher; W Britt; V A Sundqvist; L Ostberg; M Mach
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.

Authors:  Ilona Baraniak; Florian Kern; Pavlo Holenya; Paul Griffiths; Matthew Reeves
Journal:  J Infect Dis       Date:  2019-06-19       Impact factor: 5.226

3.  Antibody responses to synthetic peptides from cytomegalovirus phosphoprotein 150.

Authors:  V A Sundqvist; W Xu; B Wahren
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

4.  Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies.

Authors:  M Ohlin; V A Sundqvist; M Mach; B Wahren; C A Borrebaeck
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

5.  B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.

Authors:  Sonja Pötzsch; Nadja Spindler; Anna-Katharina Wiegers; Tanja Fisch; Pia Rücker; Heinrich Sticht; Nina Grieb; Tina Baroti; Florian Weisel; Thomas Stamminger; Luis Martin-Parras; Michael Mach; Thomas H Winkler
Journal:  PLoS Pathog       Date:  2011-08-11       Impact factor: 6.823

6.  Past and ongoing adaptation of human cytomegalovirus to its host.

Authors:  Alessandra Mozzi; Matteo Biolatti; Rachele Cagliani; Diego Forni; Valentina Dell'Oste; Chiara Pontremoli; Chiara Vantaggiato; Uberto Pozzoli; Mario Clerici; Santo Landolfo; Manuela Sironi
Journal:  PLoS Pathog       Date:  2020-05-08       Impact factor: 6.823

7.  HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.

Authors:  Cody S Nelson; Tori Huffman; Jennifer A Jenks; Eduardo Cisneros de la Rosa; Guanhua Xie; Nathan Vandergrift; Robert F Pass; Justin Pollara; Sallie R Permar
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-30       Impact factor: 12.779

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.